Clinical Trials Browser

INDUSTRY × Head and Neck Neoplasms × Docetaxel × Clear all

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Prostatic Neoplasms

NCT05076760 2025-08-29

MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors

BreastDermatologicGastrointestinalHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Melanoma, Neoplasm Metastasis, Pancreatic Neoplasms, Carcinoma, Merkel Cell, Triple Negative Breast Neoplasms

NCT00995293 2018-03-02

Taxotere (Docetaxel) New Indication: Squamous Cell Carcinoma of the Head and Neck (SCCHN) Treatment Registration Trial

Phase 3 Completed

240 enrolled

Head & Neck

Head and Neck Neoplasms

NCT00261703 2012-05-11

Docetaxel in Head and Neck Cancer

Phase 2/3 Completed

439 enrolled

Head & Neck

Head and Neck Neoplasms

NCT00242762 2011-01-27

ZD1839 (IRESSA™) in Combination With Docetaxel & Cisplatin in Subjects With Metastatic Head & Neck Cancer

Phase 2 Completed

36 enrolled

Head & Neck

Head and Neck Neoplasms

NCT00401323 2011-01-20

Taxotere (Docetaxel) in 1st Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Phase 2/3 Completed

568 enrolled

Head & Neck

Head and Neck Neoplasms, Neoplasm Metastasis, Neoplasm Recurrence, Local

NCT00521521 2009-12-07

TAX200006

Phase 2 Completed

86 enrolled

Head & Neck

Head and Neck Neoplasms

NCT00772681 2009-12-07

Tax-Nazo

Phase 4 Completed

57 enrolled

Head & Neck

Head and Neck Neoplasms

NCT00273546 2009-04-29

Induction Chemotherapy Comparing Taxotere® Cisplatin and 5-Fluorouracil (TPF) With Standard Cisplatin and 5-Fluorouracil (PF) Followed by Chemoradiation in Locally Advanced Head and Neck Cancer

Phase 3 Completed

500 enrolled

Head & Neck

Head and Neck Neoplasms, Neoplasms

Clinical Trials

Study to Assess the Effect of OCT-598 in Patients With Advanced Solid Tumors

MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors

Taxotere (Docetaxel) New Indication: Squamous Cell Carcinoma of the Head and Neck (SCCHN) Treatment Registration Trial

Docetaxel in Head and Neck Cancer

ZD1839 (IRESSA™) in Combination With Docetaxel & Cisplatin in Subjects With Metastatic Head & Neck Cancer

Taxotere (Docetaxel) in 1st Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

TAX200006

Tax-Nazo

Induction Chemotherapy Comparing Taxotere® Cisplatin and 5-Fluorouracil (TPF) With Standard Cisplatin and 5-Fluorouracil (PF) Followed by Chemoradiation in Locally Advanced Head and Neck Cancer